These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 24406026

  • 1. Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.
    Kate M, Szkotak A, Witt A, Shuaib A, Butcher K.
    J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1351-5. PubMed ID: 24406026
    [Abstract] [Full Text] [Related]

  • 2. Intravenous thrombolysis in a stroke patient taking dabigatran.
    Lee VH, Conners JJ, Prabhakaran S.
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):916.e11-2. PubMed ID: 22608344
    [Abstract] [Full Text] [Related]

  • 3. Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant.
    Folyovich A, Varga V, Béres-Molnár KA, Vadasdi K, Bereczki D.
    J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):580-2. PubMed ID: 23721623
    [Abstract] [Full Text] [Related]

  • 4. Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization.
    Sangha N, El Khoury R, Misra V, Lopez G.
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):917.e5-8. PubMed ID: 22683118
    [Abstract] [Full Text] [Related]

  • 5. Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists.
    Rybinnik I, Mullen MT, Messe S, Kasner SE, Cucchiara B.
    J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):1312-6. PubMed ID: 23313461
    [Abstract] [Full Text] [Related]

  • 6. Intravenous Thrombolysis After Idarucizumab Application in Acute Stroke Patients-A Potentially Increased Sensitivity of Thrombi to Lysis?
    Pretnar Oblak J, Sabovic M, Frol S.
    J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):768-773. PubMed ID: 30527792
    [Abstract] [Full Text] [Related]

  • 7. Stroke thrombolysis in patients taking dabigatran.
    Jayathissa S, Gommans J, Harper P.
    Intern Med J; 2013 Jul; 43(7):826-8. PubMed ID: 23841763
    [Abstract] [Full Text] [Related]

  • 8. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
    Fang CW, Tsai YT, Chou PC, Chen HM, Lu CM, Tsao CR, Chen CL, Sun MC, Shih YS, Hsieh CY, Chen LA, Chen PL, Yeh JT, Li YH.
    J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
    [Abstract] [Full Text] [Related]

  • 9. Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
    Kono S, Deguchi K, Omote Y, Yunoki T, Yamashita T, Kurata T, Ikeda Y, Abe K.
    J Neurosci Res; 2014 Jan; 92(1):46-53. PubMed ID: 24265137
    [Abstract] [Full Text] [Related]

  • 10. Good outcome after intravenous thrombolysis for acute stroke in a patient under treatment with dabigatran.
    Diogo C, Duarte J, Sobral S, Pestana P, Nzwalo H, Rita H, Sousa E Costa J.
    Am J Emerg Med; 2014 Nov; 32(11):1435.e1-2. PubMed ID: 24881517
    [Abstract] [Full Text] [Related]

  • 11. Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke.
    Beharry J, Waters MJ, Drew R, Fink JN, Wilson D, Campbell BCV, Parsons MW, Kleinig TJ, Wu TY.
    Stroke; 2020 May; 51(5):1616-1619. PubMed ID: 32208845
    [Abstract] [Full Text] [Related]

  • 12. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
    Bissig D, Manjunath R, Traylor BR, Richman DP, Ng KL.
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):e102-e104. PubMed ID: 28416406
    [Abstract] [Full Text] [Related]

  • 13. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW, Kim KJ, Noh WY, Jang MS, Yang MH, Han MK, Kwon OK, Jung C, Kim JH, Oh CW, Lee JS, Lee J, Bae HJ.
    Cerebrovasc Dis; 2013 Jun; 35(5):461-8. PubMed ID: 23735898
    [Abstract] [Full Text] [Related]

  • 14. [Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature].
    Inaishi J, Nogawa S, Mano Y, Yoshizaki T, Okada S.
    Rinsho Shinkeigaku; 2014 Jun; 54(3):238-40. PubMed ID: 24705841
    [Abstract] [Full Text] [Related]

  • 15. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study.
    García-Bermejo P, Calleja AI, Pérez-Fernández S, Cortijo E, del Monte JM, García-Porrero M, Fe Muñoz M, Fernández-Herranz R, Arenillas JF.
    Cerebrovasc Dis; 2012 Jun; 34(1):31-7. PubMed ID: 22759450
    [Abstract] [Full Text] [Related]

  • 16. CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
    Owada S, Tomita H, Kinjo T, Ishida Y, Itoh T, Sasaki K, Horiuchi D, Kimura M, Sasaki S, Okumura K.
    Thromb Res; 2015 Jan; 135(1):62-7. PubMed ID: 25466835
    [Abstract] [Full Text] [Related]

  • 17. Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience.
    Šaňák D, Jakubíček S, Černík D, Herzig R, Kunáš Z, Mikulík R, Ostrý S, Reif M, Rohan V, Tomek A, Veverka T.
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2479-2483. PubMed ID: 29807757
    [Abstract] [Full Text] [Related]

  • 18. Potential inaccuracy of point-of-care INR in dabigatran-treated patients.
    Baruch L, Sherman O.
    Ann Pharmacother; 2011 Jul; 45(7-8):e40. PubMed ID: 21712509
    [Abstract] [Full Text] [Related]

  • 19. Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report.
    Marrone LC, Marrone AC.
    Cerebrovasc Dis; 2012 Jul; 34(3):246-7. PubMed ID: 23018342
    [No Abstract] [Full Text] [Related]

  • 20. Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
    Okubo K, Kuwahara T, Takagi K, Takigawa M, Nakajima J, Watari Y, Nakashima E, Yamao K, Fujino T, Tsutsui H, Takahashi A.
    Am J Cardiol; 2015 Jun 15; 115(12):1696-9. PubMed ID: 25918026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.